Serge Saxonov Sells 9,632 Shares of 10x Genomics (NASDAQ:TXG) Stock

10x Genomics (NASDAQ:TXG) CEO Serge Saxonov sold 9,632 shares of the firm’s stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $18.58, for a total value of $178,962.56. Following the completion of the sale, the chief executive officer directly owned 1,061,924 shares of the company’s stock, valued at $19,730,547.92. The trade was a 0.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

10x Genomics Stock Performance

Shares of 10x Genomics stock opened at $22.13 on Friday. The stock has a market cap of $2.83 billion, a price-to-earnings ratio of -63.23 and a beta of 2.24. The stock has a 50 day moving average price of $19.19 and a 200-day moving average price of $15.98. 10x Genomics has a one year low of $6.78 and a one year high of $23.56.

10x Genomics (NASDAQ:TXG) last issued its quarterly earnings results on Thursday, February 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.06. The company had revenue of $166.03 million during the quarter, compared to the consensus estimate of $160.35 million. 10x Genomics had a negative return on equity of 6.89% and a negative net margin of 6.77%.10x Genomics’s revenue was up .6% on a year-over-year basis. During the same period last year, the company earned ($0.40) earnings per share. Sell-side analysts predict that 10x Genomics will post -1.43 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in 10x Genomics by 6.7% during the 3rd quarter. Vanguard Group Inc. now owns 13,274,332 shares of the company’s stock worth $155,177,000 after purchasing an additional 834,272 shares during the period. ARK Investment Management LLC grew its position in shares of 10x Genomics by 6.6% during the 4th quarter. ARK Investment Management LLC now owns 12,667,369 shares of the company’s stock worth $206,605,000 after buying an additional 779,973 shares in the last quarter. Nikko Asset Management Americas Inc. increased its stake in shares of 10x Genomics by 12.1% during the second quarter. Nikko Asset Management Americas Inc. now owns 6,009,653 shares of the company’s stock valued at $69,532,000 after buying an additional 646,997 shares during the period. Sumitomo Mitsui Trust Group Inc. increased its stake in shares of 10x Genomics by 2.1% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 5,492,189 shares of the company’s stock valued at $89,578,000 after buying an additional 110,970 shares during the period. Finally, Amova Asset Management Americas Inc. raised its holdings in shares of 10x Genomics by 2.0% in the fourth quarter. Amova Asset Management Americas Inc. now owns 5,486,153 shares of the company’s stock valued at $89,424,000 after acquiring an additional 109,270 shares in the last quarter. Institutional investors own 84.68% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on TXG shares. Zacks Research lowered shares of 10x Genomics from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 10th. Stifel Nicolaus increased their price target on 10x Genomics from $15.00 to $20.00 and gave the stock a “buy” rating in a report on Friday, February 13th. Deutsche Bank Aktiengesellschaft set a $17.00 price target on 10x Genomics and gave the stock a “hold” rating in a research note on Friday, February 13th. Leerink Partners cut their price objective on 10x Genomics from $22.00 to $20.00 and set a “market perform” rating on the stock in a research report on Tuesday, January 27th. Finally, Citigroup lowered 10x Genomics from a “buy” rating to a “cautious” rating in a research note on Thursday, December 11th. Four investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, 10x Genomics has a consensus rating of “Hold” and a consensus price target of $18.11.

Key Stories Impacting 10x Genomics

Here are the key news stories impacting 10x Genomics this week:

• Positive Sentiment: Quarterly results beat expectations: 10x reported revenue and an EPS beat in its Feb. 12 quarter (revenue roughly $166M, EPS better than consensus), which supports upside momentum and underpins recent analyst target increases. MarketBeat TXG Coverage
• Positive Sentiment: Analyst updates lifted sentiment: Several firms nudged price targets higher or reiterated constructive stances (examples cited include TD Cowen, Stifel, UBS and Canaccord), giving traders cover to buy after the earnings beat. Analyst Note
• Neutral Sentiment: Short‑interest reports appear unreliable: data entries show a large “increase” but list 0 shares / NaN and a 0.0 days‑to‑cover figure — likely a reporting glitch. This makes short‑interest an unclear signal for near‑term pressure. (No reliable link available in the alert feed.)
• Negative Sentiment: Insiders sold a material block of shares last week: CEO Serge Saxonov, CFO Adam Taich and other executives sold shares on Feb. 23 (multi‑thousand share dispositions; examples: CEO ~9,632 shares, CFO ~8,968, Benjamin Hindson ~7,826). Large insider sales can weigh on sentiment and prompt investor caution even if labeled routine diversification. InsiderTrades Alert TipRanks Coverage

10x Genomics Company Profile

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.